CN Patent

CN120456906A — Her2抑制剂的固体分散体的给药安排方案

Assigned to Boehringer Ingelheim International GmbH · Expires 2025-08-08 · 1y expired

What this patent protects

本发明涉及可用于预防和/或治疗癌症的HER2抑制剂和药学上可接受的分散体载体的固体分散体的给药安排方案，特别涉及其剂量和/或二线或另外线的施用。

USPTO Abstract

本发明涉及可用于预防和/或治疗癌症的HER2抑制剂和药学上可接受的分散体载体的固体分散体的给药安排方案，特别涉及其剂量和/或二线或另外线的施用。

Drugs covered by this patent

Hernexeos (ZONGERTINIB) · Boehringer Ingelheim

Patent Metadata

Patent number: CN120456906A
Jurisdiction: CN
Classification: —
Expires: 2025-08-08
Drug substance claim: No
Drug product claim: No
Assignee: Boehringer Ingelheim International GmbH
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.